Guggenheim analyst Michael Schmidt raised the firm’s price target on Tango Therapeutics (TNGX) to $20 from $18 and keeps a Buy rating on the shares after the company reported Q4 results and business updates, which included announcement of a new clinical trial collaboration and supply agreement to evaluate vopimetostat in combination with Erasca’s (ERAS) ERAS-0015.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target raised to $27 from $13 at H.C. Wainwright
- Midday Fly By: Stocks tumble as oil prices climb again
- Erasca, Tango Therapeutics enter clinical collaboration, supply agreement
- Tango Therapeutics reports Q4 EPS (29c), consensus (33c)
- Tango Therapeutics weakness an ‘over reaction,’ says Stifel